WEKO3
アイテム
Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area
https://repository.lib.tottori-u.ac.jp/records/4813
https://repository.lib.tottori-u.ac.jp/records/481398e7d563-e324-4546-a849-67c9496061f7
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
yam61(1)_58.pdf (785.3 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-06-22 | |||||
| タイトル | ||||||
| タイトル | Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | lymphoma, large B-cell, diffuse | |||||
| キーワード | ||||||
| 主題 | prognosis | |||||
| キーワード | ||||||
| 主題 | rituximab | |||||
| キーワード | ||||||
| 主題 | aged | |||||
| キーワード | ||||||
| 主題 | Japan | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | lymphoma, large B-cell, diffuse | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | prognosis | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | rituximab | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | aged | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Japan | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
Hosoda, Yuzuru
× Hosoda, Yuzuru× Hino, Norihiko× Motokura, Toru× Hino, Norihiko |
|||||
| 著者所属 | ||||||
| 値 | Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine / Department of Hematology, Tottori University Hospital | |||||
| 著者所属 | ||||||
| 値 | Department of Hematology, Tottori University Hospital | |||||
| 著者所属 | ||||||
| 値 | Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine | |||||
| 抄録 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 【Background】 Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. 【Methods】 The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan. 【Results】 From 2005 through 2015, 182 patients with de novo DLBCL were treated with chemotherapy in Tottori University Hospital; 154 (85%) patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) although full dose was administered in 63 (35%) patients. The median age of the patients was 71 years (range 18 to 91). Three-year overall survival rate was 71.8% (95% CI, 64.1% to 78.2%). All indices significantly discriminate risk groups for overall survival of the patients (P < 0.001). Although no statistical difference of performance was found among these indices, the best scores of model fit/discrimination measures were beaten out by age-adjusted IPI, the simplest and three-factor model. 【Conclusion】 Age-adjusted IPI is still usable in real-world practice while a better predictive model is desired for Japanese patients with DLBCL. | |||||
| 書誌情報 |
Yonago Acta Medica en : Yonago Acta Medica 巻 61, 号 1, p. 58-65, 発行日 2018-03-28 |
|||||
| 出版者 | ||||||
| 出版者 | Tottori University Faculty of Medicine | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 05135710 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00892882 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.33160/yam.2018.03.008 | |||||
| 権利 | ||||||
| 権利情報 | Yonago Acta medica 編集委員会 | |||||
| 情報源 | ||||||
| 関連名称 | Yonago Acta Medica. 2018, 61(1), 58-65 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html | |||||
| 関連名称 | http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| EISSN | ||||||
| 値 | 1346-8049 | |||||
